Merck buys Afferent for $500mm cash and $750mm in potential earn-outs
Merck & Co. Inc. agreed to pay $500mm up front to acquire Afferent Pharmaceuticals Inc., a seven-year old private biotech developing treatments for neurogenic diseases.
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com